Autolus Therapeutics (AUTL)
NASDAQ:AUTL
Want to see AUTL full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.23Last Year’s EPS
-0.18Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call reflected strong commercial momentum and operational progress: quarterly revenue surged (~191% YoY), the company achieved its first positive gross margin quarter, and production efficiency initiatives target lower per-unit costs and $15M annualized savings in 2027. Real-world data and multiple near- and mid-term clinical readouts underpin a promising pipeline and support expansion into new indications and geographies. Offsetting these positives are continued high net losses, significant cash drawdown (cash runway into Q4 2027), a sizable rise in SG&A to support commercialization, and execution risks related to manufacturing scale-up and European market access. Overall, while financial and execution risks remain, the balance of substantial commercial progress, margin improvement, and clear pipeline milestones leads to a constructive outlook.Company Guidance
Strong Quarter-over-Quarter Revenue Growth
Q1 2026 net product revenue of $26.2M versus $9.0M in Q1 2025, an increase of ~191%, driven by U.S. sales and the start of the U.K. launch (U.K. contribution minimal in Q1).
First-Time Positive Gross Margin
Shifted to a positive gross margin in Q1 2026 with $1.6M gross profit (first positive quarter after prior losses), attributed to higher volumes and manufacturing / operational improvements.
Manufacturing and Operational Efficiency Gains
Expect to produce ~2x the product in 2026 versus 2025 while keeping staffing at or below prior-year levels; implemented operational changes including a 13% workforce reduction and process optimizations to reduce hours per product.
Clear Path to Attractive Unit Economics at Peak
Company projects peak ALL gross profit margin of ~65%–70% for AUCATZYL and expects annualized savings of $15M in 2027 once restructuring impacts settle.
Clinical and Real-World Efficacy Signals
ROCCA Consortium real-world data showed strong outcomes: >90% overall response rate, no high-grade CRS reported, and only ~3% high-grade ICANS, supporting the product’s safety/efficacy profile outside trials.
Progressing Launch and Provider Coverage
Approximately 73 U.S. centers active now with plan to exceed 80 centers by year-end; U.K. already with >10 centers active and centralized NHS decision-making aiding faster rollout.
Pipeline Milestones and Development Updates
Multiple upcoming readouts: CARLYSLE follow-up and BOBCAT (progressive MS) initial data and ALARIC initial data by year-end 2026; pediatric CATULUS Phase II and potential registration alignment (data end of 2027); LUMINA Phase II (lupus nephritis) data expected in 2028.
Reiterated Full-Year Revenue Guidance
Reaffirmed 2026 net product revenue guidance of $120M–$135M, indicating management confidence in the commercial trajectory despite early-stage international rollout.
Improving Operating Losses
Loss from operations improved to $59.5M in Q1 2026 from $65.2M in Q1 2025 (an improvement of ~8.7%), reflecting revenue growth and cost actions.
AUTL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AUTL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $1.71 | $1.59 | -7.02% |
Mar 27, 2026 | $1.29 | $1.21 | -6.20% |
Nov 12, 2025 | $1.50 | $1.36 | -9.33% |
Aug 12, 2025 | $2.47 | $2.15 | -12.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Autolus Therapeutics (AUTL) report earnings?
Autolus Therapeutics (AUTL) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Autolus Therapeutics (AUTL) earnings time?
Autolus Therapeutics (AUTL) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AUTL EPS forecast?
AUTL EPS forecast for the fiscal quarter 2026 (Q2) is -0.23.